Skip to main content

Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece

Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2268. Epub 2014 Oct 26.


PMID:27202252 | DOI:10.1016/j.jval.2014.08.2268

No abstract

G Kourlaba, I Boukovinas, Z Saridaki, V Papagiannopoulou, G Tritaki, N Maniadakis


Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

View Publication